Fig. 5

EAD induces inflammatory features and DHRS3 expression. (A) Quantification of inflammation from tumor xenografts (n = 7–10/group) of treated mice (score 0–3) by pathologist blinded to nature of treatment. (B) Volcano plot (log2 fold-change (FC) vs – log10 p value) of genes upregulated and downregulated in MDA-MB-231 cells following EAD in comparison to ED treatments. (C) qRT-PCR detection of (a) CCL26 and (b) DHRS3 in MDA-MB-231 cells treated with entinostat (2.5 μM), ATRA (1 μM), and doxorubicin (200 and 12.5 nM) singly, and combinations, for 48 h; (c) western blot analysis of DHRS3 in MDA-MB-231 cells treated as described in text. Loading control: β-actin. qRT-PCR detection of DHRS3 mRNA levels in (D) tumor xenografts treated as indicated and (E) normal breast organoids (ORG), primary, and metastatic samples from TNBC patients. Mann–Whitney test performed, median of DHRS3 expression in xenograft and primary samples shown. Student’s t test performed, mean (± SEM) of CCL26 and DHRS3 expression in MDA-MB-231 cells shown. RPL39 mRNA used as control in q-RT-PCR. *p < 0.05, **p < 0.01, ***p < 0.001. E entinostat, A all-trans retinoic acid, D doxorubicin, Veh vehicle, NS not significant, NA not available